Hidetoshi Itani
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Research Subjects
Hidetoshi Itani has a total of 40 co-authors. Here are the top co-authors by number of shared publications:
- Daijiro Harada
Department of Thoracic Oncology, National Hospital Organization Shikoku Cancer Center, Matsuyama, Japan
21 shared publications - Hiroaki Okamoto
Department of Respiratory Medicine, Yokohama Municipal Citizen's Hospital, Yokohama, Japan
21 shared publications - Hiroshi Wakui
Division of Respiratory Diseases, Department of Internal Medicine The Jikei University School of Medicine Tokyo Japan
21 shared publications - Hisao Imai
Department of Respiratory Medicine, Comprehensive Cancer Center, International Medical Center Saitama Medical University Saitama Japan
21 shared publications - Kaoru Kubota
Department of Pulmonary Medicine and Oncology, Graduate School of Medicine, Nippon Medical School
21 shared publications - Kazutoshi Isobe
Division of Respiratory Medicine, Department of Internal Medicine Toho University Sakura Medical Center Sakura Japan
21 shared publications
Latest Publications
- Open Access
- 17 April 2024
- Published by Wiley in Cancer Medicine
- Vol. 13 (8) , e7188
Impact of immune‐related adverse events on survival outcomes in extensive‐stage small cell lung cancer patients treated with immune checkpoint inhibitors
Background: Immune checkpoint inhibitors have recently become the standard of care in the first‐line treatment of extensive‐stage small cell lung cancer. Although immune‐related adverse events have been reported to influence prognosis in non‐small cell lung cancer patients, few studies have investigated the prognostic value of immune‐related adverse events in small cell lung cancer patients. In this study, we evaluated the prognosis of patients who developed immune‐related adverse events after first‐line treatment with immune checkpoint inhibitor‐based chemotherapy for extensive‐stage small cell lung cancer.Methods: We enrolled 90 patients with extensive‐stage small cell lung cancer who received immune checkpoint inhibitor‐based chemotherapy as first‐line treatment from September 2019 to December 2022 in six hospitals in Japan. The patients were categorized into groups with and without immune‐related adverse events.Results: There were 23 patients with and 67 without immune‐related adverse events. Seventeen patients had grade 1–2 immune‐related adverse events, and nine (including overlapping cases) had grade ≥3. The most frequent immune‐related adverse event was a skin rash. The median survival time was 22 months in patients with immune‐related adverse events and 9.3 months in patients without immune‐related adverse events. The hazard ratio was 0.40 (95% confidence interval: 0.19–0.83, p = 0.013).Conclusions: The results of this study show that immune‐related adverse events are associated with improved survival outcomes in patients with extensive‐stage small cell lung cancer.
- 17 April 2024
- Published by Wiley in Cancer Medicine
- Vol. 13 (8) , e7188
Open AccessImpact of immune‐related adverse events on survival outcomes in extensive‐stage small cell lung cancer patients treated with immune checkpoint inhibitors
Background: Immune checkpoint inhibitors have recently become the standard of care in the first‐line treatment of extensive‐stage small cell lung cancer. Although immune‐related adverse events have been reported to influence prognosis in non‐small cell lung cancer patients, few studies have investigated the prognostic value of immune‐related adverse events in small cell lung cancer patients. In this study, we evaluated the prognosis of patients who developed immune‐related adverse events after first‐line treatment with immune checkpoint inhibitor‐based chemotherapy for extensive‐stage small cell lung cancer.Methods: We enrolled 90 patients with extensive‐stage small cell lung cancer who received immune checkpoint inhibitor‐based chemotherapy as first‐line treatment from September 2019 to December 2022 in six hospitals in Japan. The patients were categorized into groups with and without immune‐related adverse events.Results: There were 23 patients with and 67 without immune‐related adverse events. Seventeen patients had grade 1–2 immune‐related adverse events, and nine (including overlapping cases) had grade ≥3. The most frequent immune‐related adverse event was a skin rash. The median survival time was 22 months in patients with immune‐related adverse events and 9.3 months in patients without immune‐related adverse events. The hazard ratio was 0.40 (95% confidence interval: 0.19–0.83, p = 0.013).Conclusions: The results of this study show that immune‐related adverse events are associated with improved survival outcomes in patients with extensive‐stage small cell lung cancer.
- Open Access
- 15 March 2024
- Published by American Association for Cancer Research (AACR)
Supplementary Table S3 from Phase II Study of Durvalumab Immediately after Completion of Chemoradiotherapy in Unresectable Stage III Non–small Cell Lung Cancer: TORG1937 (DATE Study)
Comparison of the background between this study and the PACIFIC study
- 15 March 2024
- Published by American Association for Cancer Research (AACR)
Open AccessSupplementary Table S3 from Phase II Study of Durvalumab Immediately after Completion of Chemoradiotherapy in Unresectable Stage III Non–small Cell Lung Cancer: TORG1937 (DATE Study)
Comparison of the background between this study and the PACIFIC study
- Open Access
- 15 March 2024
- Published by American Association for Cancer Research (AACR)
Supplementary Figure S3 from Phase II Study of Durvalumab Immediately after Completion of Chemoradiotherapy in Unresectable Stage III Non–small Cell Lung Cancer: TORG1937 (DATE Study)
Onset and grade of pneumonitis
- 15 March 2024
- Published by American Association for Cancer Research (AACR)
Open AccessSupplementary Figure S3 from Phase II Study of Durvalumab Immediately after Completion of Chemoradiotherapy in Unresectable Stage III Non–small Cell Lung Cancer: TORG1937 (DATE Study)
Onset and grade of pneumonitis
- Open Access
- 15 March 2024
- Published by American Association for Cancer Research (AACR)
Supplementary Table S5 from Phase II Study of Durvalumab Immediately after Completion of Chemoradiotherapy in Unresectable Stage III Non–small Cell Lung Cancer: TORG1937 (DATE Study)
Summary of the efficacy and safety between this study and the previous studies
- 15 March 2024
- Published by American Association for Cancer Research (AACR)
Open AccessSupplementary Table S5 from Phase II Study of Durvalumab Immediately after Completion of Chemoradiotherapy in Unresectable Stage III Non–small Cell Lung Cancer: TORG1937 (DATE Study)
Summary of the efficacy and safety between this study and the previous studies
- Open Access
- 15 March 2024
- Published by American Association for Cancer Research (AACR)
Supplementary Table S5 from Phase II Study of Durvalumab Immediately after Completion of Chemoradiotherapy in Unresectable Stage III Non–small Cell Lung Cancer: TORG1937 (DATE Study)
Summary of the efficacy and safety between this study and the previous studies
- 15 March 2024
- Published by American Association for Cancer Research (AACR)
Open AccessSupplementary Table S5 from Phase II Study of Durvalumab Immediately after Completion of Chemoradiotherapy in Unresectable Stage III Non–small Cell Lung Cancer: TORG1937 (DATE Study)
Summary of the efficacy and safety between this study and the previous studies
- Open Access
- 15 March 2024
- Published by American Association for Cancer Research (AACR)
Supplementary Table S6 from Phase II Study of Durvalumab Immediately after Completion of Chemoradiotherapy in Unresectable Stage III Non–small Cell Lung Cancer: TORG1937 (DATE Study)
Phase III clinical trials with a combination of immunotherapy and radiotherapy
- 15 March 2024
- Published by American Association for Cancer Research (AACR)
Open AccessSupplementary Table S6 from Phase II Study of Durvalumab Immediately after Completion of Chemoradiotherapy in Unresectable Stage III Non–small Cell Lung Cancer: TORG1937 (DATE Study)
Phase III clinical trials with a combination of immunotherapy and radiotherapy
- Open Access
- 15 March 2024
- Published by American Association for Cancer Research (AACR)
Supplementary Table S2 from Phase II Study of Durvalumab Immediately after Completion of Chemoradiotherapy in Unresectable Stage III Non–small Cell Lung Cancer: TORG1937 (DATE Study)
Representativeness of Study Participants
- 15 March 2024
- Published by American Association for Cancer Research (AACR)
Open AccessSupplementary Table S2 from Phase II Study of Durvalumab Immediately after Completion of Chemoradiotherapy in Unresectable Stage III Non–small Cell Lung Cancer: TORG1937 (DATE Study)
Representativeness of Study Participants
- Open Access
- 15 March 2024
- Published by American Association for Cancer Research (AACR)
Supplementary Table S1 from Phase II Study of Durvalumab Immediately after Completion of Chemoradiotherapy in Unresectable Stage III Non–small Cell Lung Cancer: TORG1937 (DATE Study)
Volume definition and procedures in the radiotherapy plan
- 15 March 2024
- Published by American Association for Cancer Research (AACR)
Open AccessSupplementary Table S1 from Phase II Study of Durvalumab Immediately after Completion of Chemoradiotherapy in Unresectable Stage III Non–small Cell Lung Cancer: TORG1937 (DATE Study)
Volume definition and procedures in the radiotherapy plan
- Open Access
- 15 March 2024
- Published by American Association for Cancer Research (AACR)
Supplementary Figure S3 from Phase II Study of Durvalumab Immediately after Completion of Chemoradiotherapy in Unresectable Stage III Non–small Cell Lung Cancer: TORG1937 (DATE Study)
Onset and grade of pneumonitis
- 15 March 2024
- Published by American Association for Cancer Research (AACR)
Open AccessSupplementary Figure S3 from Phase II Study of Durvalumab Immediately after Completion of Chemoradiotherapy in Unresectable Stage III Non–small Cell Lung Cancer: TORG1937 (DATE Study)
Onset and grade of pneumonitis